• Home
  • »
  • Newsroom
  • »
  • Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab) and ...

Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

Category:

Friday, December 7, 2007 8:08 am EST

Dateline:

CHESHIRE, Conn.

Public Company Information:

NASDAQ:
ALXN

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris® (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

  • Publication Number 840: "Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy" Dr. Monica Bessler et al. -- Location: Rooms B213-B214 -- Tuesday, December 11, 2007 - 8:45 a.m. -- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302